The continued osimertinib plus chemotherapy overcoming resistance after histologic transformation in EGFR-mutant lung adenocarcinoma treated with osimertinib.

被引：0
|
作者：
Kang, Jin
Li, Xiang-Meng
Cheng, Jia-Tao
Chen, Huajun
Zhang, Xuchao
Tu, Hai-Yan
Zhou, Qing
Wu, Yi-Long
Yang, Jin-Ji
机构：
[1] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
[3] Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangdong Prov Key Lab Translat Med Lung Canc, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e20615
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20615
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Osimertinib in EGFR-mutant non-small cell lung carcinoma
    Lorenz, Judith
    [J]. PNEUMOLOGIE, 2023, 77 (11): : 847 - 847
  • [32] INSIGHT 2: Tepotinib plus Osimertinib in EGFR-Mutant NSCLC with Resistance to 1st-Line Osimertinib due to MET Amplification
    Smit, E.
    Felip, E.
    Karachaliou, N.
    Ellers-Lenz, B.
    Wu, Y. -L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S36 - S36
  • [33] Tepotinib plus osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2
    Wu, Y-L.
    Dooms, C.
    Nadal, E.
    Raskin, J.
    Demedts, I.
    Mazieres, J.
    Wislez, M.
    Abdul Shukor, S.
    Tho, L. M.
    Wang, C-C.
    Viteri, S.
    Le, X.
    How, S. H.
    Tan, D.
    Takeda, M.
    Veillon, R.
    Karachaliou, N.
    Ellers-Lenz, B.
    Smit, E. F. F.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1036 - S1036
  • [34] Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
    Zang, Hongjing
    Qian, Guoqing
    Arbiser, Jack
    Owonikoko, Taofeek K.
    Ramalingam, Suresh S.
    Fan, Songqing
    Sun, Shi-Yong
    [J]. MOLECULAR ONCOLOGY, 2020, 14 (04) : 882 - 895
  • [35] MERTK activation drives osimertinib resistance in EGFR-mutant non small cell lung cancer
    Yan, Dan
    Huelse, Justus M.
    Kireev, Dmitri
    Tan, Zikang
    Chen, Luxiao
    Goyal, Subir
    Wang, Xiaodong
    Frye, Stephen, V
    Behera, Madhusmita
    Schneider, Frank
    Ramalingam, Suresh S.
    Owonikoko, Taofeek
    Earp, H. Shelton
    DeRyckere, Deborah
    Graham, Douglas K.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (15):
  • [36] Acquired ALK and RET Gene Fusions as Mechanisms of Resistance to Osimertinib in EGFR-Mutant Lung Cancers
    Offin, Michael
    Somwar, Romel
    Rekhtman, Natasha
    Benayed, Ryma
    Chang, Jason C.
    Plodkowski, Andrew
    Lui, Allan J. W.
    Eng, Juliana
    Rosenblum, Marc
    Li, Bob T.
    Riely, Gregory J.
    Rudin, Charles M.
    Kris, Mark G.
    Travis, William
    Drilon, Alexander
    Arcila, Maria E.
    Ladanyi, Marc
    Yu, Helena A.
    [J]. JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 12
  • [37] Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer
    Cai, Xueting
    Miao, Jing
    Sun, Rongwei
    Wang, Sainan
    Molina-Vila, Miguel Angel
    Chaib, Imane
    Rosell, Rafael
    Cao, Peng
    [J]. PHARMACOLOGICAL RESEARCH, 2021, 170
  • [38] Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
    Takamori, Shinkichi
    Seto, Takashi
    Yamaguchi, Masafumi
    Kinoshita, Fumihiko
    Fujishita, Takatoshi
    Ito, Kensaku
    Toyozawa, Ryo
    Shoji, Fumihiro
    Okamoto, Tatsuro
    [J]. FRONTIERS IN ONCOLOGY, 2022, 12
  • [39] Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib
    Kang, Jin
    Chen, Hua-Jun
    Wang, Zheng
    Liu, Jing
    Li, Bing
    Zhang, Tengfei
    Yang, Zhenfan
    Wu, Yi-Long
    Yang, Jin-Ji
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : E49 - E53
  • [40] Osimertinib Regresses an EGFR-Mutant Cisplatinum- Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice
    Higuchi, Takashi
    Oshiro, Hiromichi
    Zhang, Zhiying
    Miyake, Kentaro
    Sugisawa, Norihiko
    Katsuya, Yuki
    Yamamoto, Norio
    Hayashi, Katsuhiro
    Kimura, Hiroaki
    Miwa, Shinji
    Igarashi, Kentaro
    Zhao, Ming
    Bouvet, Michael
    Sing, Shree Ram
    Tsuchiya, Hiroyuki
    Hoffman, Robert M.
    [J]. TRANSLATIONAL ONCOLOGY, 2019, 12 (04): : 640 - 645
12345